Why the study?
Does withdrawal of guideline-directed medical therapy increase mortality/morbidity in patients with heart failure and improved ejection fraction?
Does withdrawal of guideline-directed medical therapy increase mortality/morbidity in patients with heart failure and improved ejection fraction?
Answers are grounded in this paper and cite their sources.
Withdrawing RASi/ARNi and MRA in patients with HFimpEF is associated with worse 1-year outcomes, supporting the continuation of these therapies.
In patients with HF with improved EF, HF therapy withdrawal was rare. Withdrawing RASi/ARNi and MRA was associated with higher mortality/morbidity at 1 year. No association was found for BBL withdrawal, albeit with a significant heterogeneity for EF at improvement, suggesting better outcomes with continuing BBL only until EF improves up to 50%. These results are hypothesis-generating and highlight the need for randomized controlled trials testing BBL withdrawal in patients with HF with improved EF.
No takes yet. Share an insight, caveat, or question.
Basile et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: